• Je něco špatně v tomto záznamu ?

Endothelial Progenitor Cells Produced From Human Pluripotent Stem Cells by a Synergistic Combination of Cytokines, Small Compounds, and Serum-Free Medium

S. Farkas, P. Simara, D. Rehakova, L. Veverkova, I. Koutna,

. 2020 ; 8 (-) : 309. [pub] 20200515

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019190

Human pluripotent stem cells (hPSCs) are a promising source of autologous endothelial progenitor cells (EPCs) that can be used for the treatment of vascular diseases. However, this kind of treatment requires a large amount of EPCs. Therefore, a highly efficient, robust, and easily reproducible differentiation protocol is necessary. We present a novel serum-free differentiation protocol that exploits the synergy of multiple powerful differentiation effectors. Our protocol follows the proper physiological pathway by differentiating EPCs from hPSCs in three phases that mimic in vivo embryonic vascular development. Specifically, hPSCs are differentiated into (i) primitive streak, which is subsequently turned into (ii) mesoderm, which finally differentiates into (iii) EPCs. This differentiation process yields up to 15 differentiated cells per seeded hPSC in 5 days. Endothelial progenitor cells constitute up to 97% of these derived cells. The experiments were performed on the human embryonic stem cell line H9 and six human induced pluripotent stem cell lines generated in our laboratory. Therefore, robustness was verified using many hPSC lines. Two previously established protocols were also adapted and compared to our synergistic three-phase protocol. Increased efficiency and decreased variability were observed for our differentiation protocol in comparison to the other tested protocols. Furthermore, EPCs derived from hPSCs by our protocol expressed the high-proliferative-potential EPC marker CD157 on their surface in addition to the standard EPC surface markers CD31, CD144, CD34, KDR, and CXCR4. Our protocol enables efficient fully defined production of autologous endothelial progenitors for research and clinical applications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019190
003      
CZ-PrNML
005      
20201123123906.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcell.2020.00309 $2 doi
035    __
$a (PubMed)32509776
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Farkas, Simon $u Department of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia.
245    10
$a Endothelial Progenitor Cells Produced From Human Pluripotent Stem Cells by a Synergistic Combination of Cytokines, Small Compounds, and Serum-Free Medium / $c S. Farkas, P. Simara, D. Rehakova, L. Veverkova, I. Koutna,
520    9_
$a Human pluripotent stem cells (hPSCs) are a promising source of autologous endothelial progenitor cells (EPCs) that can be used for the treatment of vascular diseases. However, this kind of treatment requires a large amount of EPCs. Therefore, a highly efficient, robust, and easily reproducible differentiation protocol is necessary. We present a novel serum-free differentiation protocol that exploits the synergy of multiple powerful differentiation effectors. Our protocol follows the proper physiological pathway by differentiating EPCs from hPSCs in three phases that mimic in vivo embryonic vascular development. Specifically, hPSCs are differentiated into (i) primitive streak, which is subsequently turned into (ii) mesoderm, which finally differentiates into (iii) EPCs. This differentiation process yields up to 15 differentiated cells per seeded hPSC in 5 days. Endothelial progenitor cells constitute up to 97% of these derived cells. The experiments were performed on the human embryonic stem cell line H9 and six human induced pluripotent stem cell lines generated in our laboratory. Therefore, robustness was verified using many hPSC lines. Two previously established protocols were also adapted and compared to our synergistic three-phase protocol. Increased efficiency and decreased variability were observed for our differentiation protocol in comparison to the other tested protocols. Furthermore, EPCs derived from hPSCs by our protocol expressed the high-proliferative-potential EPC marker CD157 on their surface in addition to the standard EPC surface markers CD31, CD144, CD34, KDR, and CXCR4. Our protocol enables efficient fully defined production of autologous endothelial progenitors for research and clinical applications.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Simara, Pavel $u Department of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Rehakova, Daniela $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Veverkova, Lenka $u I. Surgery Department, St. Anne's University Hospital Brno, Brno, Czechia.
700    1_
$a Koutna, Irena $u Department of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
773    0_
$w MED00186212 $t Frontiers in cell and developmental biology $x 2296-634X $g Roč. 8, č. - (2020), s. 309
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32509776 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123905 $b ABA008
999    __
$a ind $b bmc $g 1585970 $s 1109388
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c - $d 309 $e 20200515 $i 2296-634X $m Frontiers in cell and developmental biology. $n Front Cell Dev Biol $x MED00186212
LZP    __
$a Pubmed-20201103

Najít záznam

Citační ukazatele

Možnosti archivace